Back to top
more

Glaukos (GKOS)

(Delayed Data from NYSE)

$119.82 USD

119.82
617,615

+2.17 (1.84%)

Updated Jul 26, 2024 04:00 PM ET

After-Market: $119.74 -0.08 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (100 out of 251)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

DaVita (DVA) Ties Up with Cigna Arm, Expands in Los Angeles

DaVita HealthCare Partners Inc. (DVA), a leading provider of dialysis services, announced that HealthCare Partners, a unit within its medical group, has entered into a strategic partnership with Cigna, a global health insurance service company.

    Henry Schein (HSIC) Tops Q4 Earnings, Reaffirms '17 View

    Henry Schein, Inc. (HSIC) reported adjusted earnings per share of $1.88 in the fourth quarter of 2016, up 12.6% year over year and surpassed the Zacks Consensus Estimate by 2.2%.

      Ecolab's (ECL) Earnings, Revenues Miss Estimates in Q4

      Ecolab Inc. (ECL) reported fourth-quarter 2016 adjusted earnings of $1.25 per share, which missed the Zacks Consensus Estimate of $1.27.

        Medtronic (MDT) Beats on Q3 Earnings, Retains Sales View

        Medtronic plc'S (MDT) third-quarter fiscal 2017 Adjusted earnings per share (EPS) came in at $1.12, a penny ahead of the Zacks Consensus Estimate.

          Henry Schein to Acquire SAS to Strengthen Dental Offerings

          Henry Schein Inc. (HSIC) announced its decision to acquire Southern Anesthesia + Surgical (SAS).

            DENTSPLY (XRAY) Beats on Earnings in Q4, Misses Revenues

            DENTSPLY SIRONA Inc. (XRAY) reported adjusted earnings per share of 67 cents in the fourth quarter of 2016, surpassing the Zacks Consensus Estimate by 2 cents.

              Zacks.com featured highlights: Xcerra, Glaukos, Nova Measuring Instruments, Customers Bancorp and DNB Financial

              Zacks.com featured highlights: Xcerra, Glaukos, Nova Measuring Instruments, Customers Bancorp and DNB Financial

                Allscripts (MDRX) Q4 Earnings Miss Estimates, View Upbeat

                Allscripts Healthcare Solutions, Inc.(MDRX) reported fourth-quarter 2016 earnings of 10 cents per share, which missed the Zacks Consensus Estimate by 2 cents.

                  DaVita (DVA) Earnings Beat Estimates, Revenues Lag in Q4

                  DaVita Inc. (DVA) reported fourth-quarter 2016 adjusted operating earnings of 98 cents per share that surpassed the Zacks Consensus Estimate of 91 cents.

                    GNC Holdings (GNC) Misses Q4 Earnings, Revenues Decline Y/Y

                    GNC Holdings Inc. (GNC) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 37 cents, down 88.1% and also missed the Zacks Consensus Estimate by 81.1%.

                      Medtronic's Freezor Xtra Catheter Gains FDA Nod for AVNRT

                      Medtronic plc (MDT) recently announced the receipt of U.S. FDA approval for its Freezor Xtra Cryoablation Catheter to treat patients with atrioventricular nodal re-entrant tachycardia.

                        LabCorp (LH) Q4 Earnings and Revenues Beat, Offers View

                        Laboratory Corporation of America Holdings (LH) or LabCorp reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.15, up 8.6% from the year-ago quarter.

                          Chemed (CHE) Misses Q4 Earnings, Sales; Offers '17 View

                          Chemed Corp.'s (CHE) fourth-quarter 2016 adjusted earnings per share (EPS) was $2.02, missing the Zacks Consensus Estimate by 4.3%.

                            Omnicell (OMCL) Q4 Earnings Deteriorate Y/Y, Revenues Miss

                            Omnicell, Inc. (OMCL) reported a breakeven in fourth-quarter 2016 earnings per share (EPS), a deterioration from the year-ago earnings of 5 cents.

                              Masimo Gets CE Mark for RRp on MightySat Rx Pulse Oximeter

                              Masimo Corporation (MASI) recently announced the receipt of CE mark approval for respiration rate measurement (RRp) on MightySat Rx fingertip pulse oximeter.

                                CryoLife (CRY) Earnings Beat Estimates, Revenues Lag in Q4

                                CryoLife, Inc. (CRY) posted fourth-quarter 2016 adjusted earnings per share of 12 cents, beating the Zacks Consensus Estimate of 8 cents.

                                  Cynosure (CYNO) to be Acquired by Hologic in $1.65B Deal

                                  Cynosure, Inc. (CYNO), announced that it has entered into a definitive merger agreement with Hologic, Inc. (HOLX).

                                    Express Scripts (ESRX) Earnings Top, Revenues Lag in Q4

                                    Express Scripts Holding Company (ESRX) posted fourth-quarter 2016 adjusted earnings per share of $1.88, beating the Zacks Consensus Estimate by a penny

                                      Genomic Health (GHDX) Earnings Surpass Estimates in Q4

                                      Genomic Health, Inc. (GHDX) reported fourth-quarter 2016 earnings per share of 4 cents, reflecting an improvement from the year-ago quarter's loss figure of 8 cents.

                                        Becton, Dickinson Launches BD Resolve Early Access Program

                                        Leading global medical technology company, Becton, Dickinson and Company (BDX), popularly known as BD, recently announced an early access program for the BD Resolve Single-Cell Gene Expression platform.

                                          Medtronic (MDT) Adds New Tools, Expands Coronary Suite

                                          Medtronic plc (MDT) recently added DxTerity Diagnostic Angiography Catheter line and several transradial-specific products to its market-leading coronary portfolio.

                                            Bruker (BRKR) Beats on Q4 Earnings, Issues 2017 Guidance

                                            Bruker Corporation (BRKR) reported fourth quarter 2016 adjusted EPS of 46 cents, up 21.1% year over year and also surpassed the Zacks Consensus Estimate of 37 cents.

                                              Omnicell Partners with DCH Health for Sterile Compounding

                                              Omnicell, Inc. (OMCL) recently formed an alliance with West Alabama's community-based health service provider, DCH Health System on sterile compounding operations.

                                                Varian (VAR) Wins Competitive Bid for Six Shanghai Hospitals

                                                Varian Medical Systems, Inc. (VAR) recently announced that it has won a competitive bid in Shanghai.

                                                  STERIS (STE) Cuts 2017 View: Will it See Gloomy Days Ahead?

                                                  On Feb 09, we issued an updated research report on Ohio-based STERIS plc (STE).